Understanding Pregnancy Discrimination and Your Rights in New Jersey
Welcoming a child into the world should be a joyful and exciting time—not one overshadowed by fear of losing your job or being treated unfairly at work. Unfortunately, many women in New Jersey still face discrimination in the workplace due to pregnancy, childbirth, or related medical conditions.
At NJ Employment Lawyers, LLC, we advocate for the rights of working mothers and expectant employees. If your employer has denied accommodations, treated you differently, or retaliated against you because of your pregnancy, you may have a legal claim for pregnancy discrimination.
Pregnancy discrimination is a form of unlawful employment discrimination that occurs when an employee or job applicant is treated unfavorably due to pregnancy, childbirth, or a related medical condition. It can take many forms, including: Refusing to hire or promote a pregnant person
Reducing work hours or responsibilities after learning of a pregnancy
Forcing an employee to take leave even though they are able and willing to work
Failing to provide reasonable accommodations, such as modified tasks or schedules
Firing or disciplining someone for taking maternity or family leave
Such conduct is prohibited under both the federal Pregnancy Discrimination Act (PDA) and the New Jersey Law Against Discrimination (NJLAD).
In New Jersey, employers are required to provide reasonable accommodations for pregnant employees, including changes to job duties or work schedules when medically advised. These accommodations might include: Allowing more frequent breaks
Light-duty assignments
Temporary transfers to less hazardous roles
Time off to recover from childbirth
Employers may not retaliate against an employee for requesting accommodations. Denying these requests without justification may constitute discrimination.
Employees in New Jersey may qualify for job-protected leave under multiple statutes, including: Family and Medical Leave Act (FMLA) – Up to 12 weeks of unpaid, job-protected leave for childbirth and bonding with a new child.
– Up to 12 weeks of unpaid, job-protected leave for childbirth and bonding with a new child. New Jersey Family Leave Act (NJFLA) – Similar protections for bonding leave, often usable consecutively with FMLA.
– Similar protections for bonding leave, often usable consecutively with FMLA. New Jersey Temporary Disability Benefits – Provides partial wage replacement during pregnancy and recovery.
– Provides partial wage replacement during pregnancy and recovery. New Jersey Family Leave Insurance (FLI) – Pays a portion of wages while bonding with a newborn or caring for a family member.
If your employer discourages, penalizes, or terminates you for using these leave entitlements, that may be grounds for legal action.
Wondering if you've experienced pregnancy discrimination? Some red flags include: A sudden change in your performance reviews after announcing your pregnancy
Exclusion from meetings, training, or advancement opportunities
Being told your pregnancy will 'interfere' with your duties
Discipline or job loss shortly after taking maternity leave
Each of these may be more than just poor treatment—they could be legal violations under state and federal law.
We understand how emotionally and financially stressful pregnancy discrimination can be. Our attorneys at NJ Employment Lawyers, LLC will take the time to understand your experience, gather evidence, and fight for the compensation and accountability you deserve.
We've successfully handled cases involving layoffs during maternity leave, denied accommodations, and retaliation for using family leave. Whether through settlement negotiations or courtroom litigation, we work tirelessly to protect your rights and restore your peace of mind.
If you're experiencing pregnancy discrimination in New Jersey, you don't have to face it alone. Reach out to our team today to take the first step toward justice.
Address:101 Eisenhower Pkwy #300
Roseland, NJ 07068
Phone: (973) 358-7027
About Us:
NJ Employment Lawyers, LLC represents employees across New Jersey in pregnancy discrimination, wrongful termination, retaliation, and other employment law matters. We are proud to defend the rights of working parents every day.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Pantai Hospital Kuala Lumpur Advances Adult Congenital Heart Care with First Minimally Invasive PDA Device Closure
KUALA LUMPUR, Malaysia, June 6, 2025 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) marked a significant milestone in cardiovascular care with the successful transcatheter device occlusion of a patent ductus arteriosus (PDA) in an adult patient with congenital heart disease — a first for the hospital's Interventional Cardiology Laboratory (ICL). The patient, who was initially referred for open-heart surgery involving PDA ligation and ventricular septal defect (VSD) closure, was carefully evaluated by PHKL's multidisciplinary cardiac team. A detailed transoesophageal echocardiogram (TOE) revealed a single tiny VSD that did not require immediate surgical repair, allowing the team to opt for a less invasive, catheter-based approach. "This case is a testament to multidisciplinary, patient-centred approach," said Dr Siti Laura, Consultant Paediatric Cardiothoracic Surgeon at PHKL. "By opting for a minimally invasive PDA device occlusion, we were able to offer the patient a faster recovery, smaller incision, and significantly reduced scarring." This successful procedure highlights PHKL's expanding capabilities in adult congenital heart care, a specialised and growing field that requires collaborative planning and tailored interventions. It also reflects the hospital's commitment to delivering innovative, minimally invasive solutions for structural heart conditions in adults — a group often underrepresented in congenital cardiac care Our ability to perform such procedures reflects the hospital's continuous investment in advanced cardiac technology and our commitment to improving outcomes for patients with congenital heart disease," Dr Siti Laura added. "We will continue to monitor the patient's condition closely — particularly her VSD — to ensure optimal long-term care. PHKL reinforces its position as a tertiary referral centre and a growing centre of excellence for adult congenital heart disease management in Malaysia. For more information about Paediatric and Congenital Cardiothoracic Services at PHKL, please visit: -END- *** Dr Siti Laura Mazalan, Consultant Paediatric and Congenital Cardiothoracic Surgeon MBBS (University of Malaya, Malaysia), MMed Surg (University Kebangsaan Malaysia, Malaysia), Fellowship in Paediatric Cardiac Surgery (Birmingham Children Hospital, United Kingdom) Dr. Siti Laura is a highly accomplished Paediatric Cardiothoracic Surgeon deeply committed to serving vulnerable in Malaysia. Her medical journey commenced with an MBBS from the University of Malaya in 1998, followed by a Master of Medicine (Surgery) from Universiti Kebangsaan Malaysia in 2004. Beginning her career at Institute Jantung Negara in 2004, she devoted 14 years to the institution as a Consultant Cardiothoracic Surgeon. Motivated by her dedication to enhancing healthcare, she pursued a transformative one-year Fellowship in Paediatric Cardiac Surgery at Birmingham Children's Hospital in 2010. In 2020, Dr. Siti Laura joined Serdang Hospital, where she played a pivotal role in establishing the Paediatric Cardiothoracic service, catering to underprivileged children with congenital heart diseases in the nation. She subsequently became a Consultant Paediatric Cardiothoracic Surgeon at Pantai Hospital Kuala Lumpur. Dr Siti Laura's area of interest includes Neonatal and Paediatric Cardiothoracic Surgery, Adult Congenital Cardiac Surgery, Single Ventricle Heart Surgery, ECMO support (Extracorporeal membrane oxygenation), Slide Tracheoplasty Surgery in neonates and paediatric patients and Cardiac Homograft Banking. Dr Siti Laura's expertise and unwavering dedication continue to make a profound impact on the lives of her patients and the healthcare community. *** About Pantai Hospital Kuala Lumpur For five decades, Pantai Hospital Kuala Lumpur has been the heartbeat of Kuala Lumpur, steadfastly delivering exceptional care to patients from all walks of life. Since its inception in 1974 with just 68 beds and 20 medical specialists, the hospital has grown into a healthcare icon today with 507 beds, over 200 consultants and counting. Our pursuit of quality healthcare, clinical excellence, and cutting-edge technology is underscored by our service quality and dedication towards clinical research. This has earned us accreditations from the Malaysian Society for Quality in Health (MSQH) and the Joint Commission International (JCI). Additionally, we hold certification as a Baby-Friendly Hospital and is a preferred hospital in Malaysia by the World Health Organization (WHO). As we celebrate our 50th anniversary, Pantai Hospital Kuala Lumpur looks to the future, unwaveringly committed to continuing its legacy of excellence with world-class healthcare services and innovative treatments for generations to come. Learn more at For more information, please contact:Callie Phin, Pantai Hospital Kuala LumpurEmail: Tel No.: 014-686 7066 For media enquiry:Natasha Loo, PR Lab ConsultancyEmail: tasha@ Tel No.: 010-231 0110 Lim Joe Ee, PR Lab ConsultancyEmail: Tel No.: 012-635 9839 Ally Chai, PR Lab ConsultancyEmail: ally@ Tel No.: 016-232 7625 View original content to download multimedia: SOURCE Pantai Hospital Kuala Lumpur
Miami Herald
a day ago
- Miami Herald
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
NEW YORK CITY, NEW YORK / ACCESS Newswire / June 5, 2025 / New to The Street, the nation's leading multi-platform financial news show, today announced it has signed a 12-part media partnership with NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company focused on life-saving therapies for patients with suicidal depression, PTSD, and chronic pain. The partnership will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, providing updates from the front lines of biotech innovation. As part of the comprehensive campaign, New to The Street will also produce earned media placements on ABC, NBC, and CBS affiliates, a full suite of nationally aired TV commercials, and premium outdoor billboard exposure in Times Square and throughout the NYC Financial District. The series begins airing later this month on Fox Business and Bloomberg Television as sponsored programming, reaching more than 245 million homes weekly across the U.S. and Middle East. Episodes will also stream on New to The Street's YouTube channel, which now exceeds 2.5 million subscribers, and be supported by billboard takeovers in Times Square and full media amplification through the NewsOut™ and platforms. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders. Its lead investigational drug, NRX-101, has been granted FDA Breakthrough Therapy and Fast Track Designation for suicidal bipolar depression. The company is also pursuing accelerated approval for preservative-free IV ketamine (NRX-100) and advancing additional treatments for PTSD, chronic pain, and UTIs. Learn more at About New to The Street New to The Street is a leading branded content TV series that features innovative public and private companies on national television, including Fox Business and Bloomberg Television. With more than 2.52 million YouTube subscribers, a reach of 245 million TV households, and a powerful outdoor media footprint, the platform offers unmatched exposure across digital, television, and out-of-home channels. Learn more at Media Contact:Monica BrennanPR Coordinator, New to The StreetEmail: Monica@ SOURCE: New To The Street
Time Business News
2 days ago
- Time Business News
Engaging with Regulatory Bodies on Responsible UK Vape Sales
The landscape of vape sales in the UK is uniquely shaped by stringent regulations designed to protect public health and guide ethical business practices. For vape retailers and manufacturers, compliance is more than a legal requirement—it is a cornerstone of responsible commercial conduct. Engaging proactively with regulatory bodies not only ensures operational alignment with current laws but also reinforces consumer trust, supports public safety, and secures the long-term sustainability of the industry. In a market subject to evolving legislation and heightened scrutiny, meaningful engagement with authorities is a strategic necessity. In today's competitive vaping market, retailers need efficient ways to manage inventory and reduce costs while meeting customer demand. One effective strategy is to purchase products in larger quantities, which helps secure better pricing and ensures consistent stock availability. Many businesses benefit from bulk buy vapes options, allowing them to acquire a wide range of popular devices and e-liquids at discounted rates. This approach not only improves profit margins but also provides flexibility to respond quickly to market trends. By leveraging bulk purchasing, retailers can strengthen their supply chain and build stronger customer loyalty through reliable product availability. The regulatory environment for vape sales in the UK is governed by multiple agencies, each with distinct responsibilities. The Medicines and Healthcare products Regulatory Agency (MHRA) oversees product notifications and ensures compliance with the Tobacco and Related Products Regulations (TRPR). The Advertising Standards Authority (ASA) enforces marketing standards, while Trading Standards conducts checks on labelling, age restrictions, and in-store practices. Staying informed of each agency's expectations is essential. These bodies not only set the framework within which vape businesses must operate, but they also offer guidance, resources, and channels for dialogue. Understanding their functions enables more effective communication, compliance, and responsiveness in the face of industry shifts. Engaging with regulators should not be reactive or limited to times of audit or investigation. Proactive communication—such as seeking clarification on guidelines, requesting feedback on proposed product labels, or attending public consultations—positions a business as responsible and committed to public health objectives. When vape companies reach out to authorities before launching a product or campaign, they reduce the risk of penalties and demonstrate a genuine intent to align with industry standards. Regular interaction also provides the opportunity to influence policy development by sharing data, consumer insights, and innovations that can help shape balanced, evidence-based regulation. UK vape legislation is subject to regular updates, particularly in response to scientific research, public health trends, and political agendas. Businesses that remain passive risk falling out of compliance, often unknowingly. Subscribing to official channels, participating in industry webinars, and engaging with trade associations offer vital access to real-time information and policy updates. A business that integrates these updates into its operational workflow is better prepared to adapt swiftly. Whether it's revising packaging to reflect new warning requirements or adjusting sales processes to incorporate updated age verification rules, responsiveness is a marker of maturity and ethical commitment. Regulatory bodies occasionally open public or industry consultations to gather input on proposed legislation or amendments. Vape businesses should view these as opportunities to participate in shaping the rules that govern them. Submitting informed responses or attending policy forums allows businesses to advocate for fair, practical regulations that protect consumers while preserving commercial viability. In addition to formal consultations, engaging with trade bodies such as the UK Vaping Industry Association (UKVIA) provides a unified voice in policy discussions. These organisations often act as intermediaries between regulators and the industry, helping ensure that business realities are considered in the drafting of new rules. A business's ability to engage meaningfully with regulators depends on the strength of its internal compliance infrastructure. This includes having dedicated compliance officers, maintaining accurate product records, implementing rigorous staff training, and conducting regular audits of sales and marketing practices. Such structures not only facilitate engagement with external bodies but also signal credibility and professionalism. When regulatory inspections occur, businesses with organised documentation and transparent processes are more likely to receive cooperative treatment and constructive feedback rather than punitive action. Compliance is often seen as a cost, but proactive engagement can also serve as a competitive differentiator. Brands known for working constructively with regulators are often viewed more favourably by consumers, retailers, and investors. They attract partnerships with like-minded suppliers, are less likely to face disruption from enforcement action, and are better positioned to expand into other regulated markets. Furthermore, as regulators increasingly focus on sustainability, youth protection, and product safety, engaged companies are more likely to anticipate and adapt to future requirements. This agility allows them to innovate confidently while avoiding costly delays or recalls. Ultimately, regulatory engagement must be rooted in a broader cultural commitment to ethical responsibility. This means embedding compliance into every facet of the business—from marketing and product development to customer service and training. Leaders must communicate clearly that regulatory alignment is not optional or superficial, but central to the brand's identity. In turn, this fosters trust among customers and regulators alike. Authorities are more inclined to support companies that demonstrate respect for the rules and contribute positively to the broader public health mission. A collaborative relationship creates a safer, more transparent industry for everyone involved. The demand for vaping products continues to rise across the UK, prompting retailers to find reliable sources that offer both variety and competitive pricing. Access to a broad selection of high-quality items is essential for businesses looking to attract and retain customers. One effective way to achieve this is through vape wholesale UK, which provides retailers with the opportunity to purchase products in bulk while benefiting from local expertise and compliance with regulations. This model helps businesses maintain consistent stock levels, reduce costs, and quickly adapt to market trends, ultimately supporting sustainable growth in a competitive industry. Engaging with regulatory bodies is an essential component of responsible vape sales in the UK. It transforms compliance from a reactive task into a proactive strategy that protects consumers, enhances brand reputation, and supports sustainable growth. By communicating regularly, participating in policy development, and strengthening internal systems, vape businesses position themselves as trusted stakeholders in a heavily scrutinised market. In a sector defined by rapid evolution and public accountability, building strong, transparent relationships with regulators is not just advisable—it is indispensable. TIME BUSINESS NEWS
